Answer
Raltegravir inhibits the catalytic activity of HIV-1 integrase, preventing integration of the viral genome into the host cell genome, so the unintegrated HIV genome cannot direct production of new infectious viral particles.
Sources for this answer
- Isentress 400 mg Film-coated TabletsMerck Sharp & Dohme (UK) Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 37Document updated
Sources checked